vs
Side-by-side financial comparison of DIODES INC (DIOD) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
DIODES INC is the larger business by last-quarter revenue ($391.6M vs $177.4M, roughly 2.2× Pacira BioSciences, Inc.). DIODES INC runs the higher net margin — 2.6% vs 1.6%, a 1.0% gap on every dollar of revenue. On growth, DIODES INC posted the faster year-over-year revenue change (15.4% vs 5.0%). Over the past eight quarters, DIODES INC's revenue compounded faster (13.9% CAGR vs -0.2%).
Diodes Incorporated is a global semiconductor manufacturer that designs, produces and supplies discrete, analog and mixed-signal semiconductor products. Its solutions serve key end markets including automotive, industrial, consumer electronics, personal computing and communications infrastructure, with a worldwide customer base.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
DIOD vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $391.6M | $177.4M |
| Net Profit | $10.2M | $2.9M |
| Gross Margin | 31.1% | — |
| Operating Margin | 3.4% | 3.9% |
| Net Margin | 2.6% | 1.6% |
| Revenue YoY | 15.4% | 5.0% |
| Net Profit YoY | 23.8% | — |
| EPS (diluted) | $0.23 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $391.6M | $196.9M | ||
| Q3 25 | $392.2M | $179.5M | ||
| Q2 25 | $366.2M | $181.1M | ||
| Q1 25 | $332.1M | $168.9M | ||
| Q4 24 | $339.3M | $187.3M | ||
| Q3 24 | $350.1M | $168.6M | ||
| Q2 24 | $319.8M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $10.2M | — | ||
| Q3 25 | $14.3M | $5.4M | ||
| Q2 25 | $46.1M | $-4.8M | ||
| Q1 25 | $-4.4M | $4.8M | ||
| Q4 24 | $8.2M | — | ||
| Q3 24 | $13.7M | $-143.5M | ||
| Q2 24 | $8.0M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 31.1% | 79.5% | ||
| Q3 25 | 30.7% | 80.9% | ||
| Q2 25 | 31.5% | 77.4% | ||
| Q1 25 | 31.5% | 79.7% | ||
| Q4 24 | 32.7% | 78.7% | ||
| Q3 24 | 33.7% | 76.9% | ||
| Q2 24 | 33.6% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 3.4% | 1.2% | ||
| Q3 25 | 3.0% | 3.5% | ||
| Q2 25 | 2.6% | 4.7% | ||
| Q1 25 | 0.4% | 1.2% | ||
| Q4 24 | 3.5% | 13.2% | ||
| Q3 24 | 6.2% | -82.8% | ||
| Q2 24 | 1.2% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 2.6% | — | ||
| Q3 25 | 3.6% | 3.0% | ||
| Q2 25 | 12.6% | -2.7% | ||
| Q1 25 | -1.3% | 2.8% | ||
| Q4 24 | 2.4% | — | ||
| Q3 24 | 3.9% | -85.1% | ||
| Q2 24 | 2.5% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.23 | $0.05 | ||
| Q3 25 | $0.31 | $0.12 | ||
| Q2 25 | $0.99 | $-0.11 | ||
| Q1 25 | $-0.10 | $0.10 | ||
| Q4 24 | $0.18 | $0.38 | ||
| Q3 24 | $0.30 | $-3.11 | ||
| Q2 24 | $0.17 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $377.0M | $144.3M |
| Total DebtLower is stronger | $25.7M | — |
| Stockholders' EquityBook value | $1.9B | $653.9M |
| Total Assets | $2.4B | $1.2B |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $377.0M | $238.4M | ||
| Q3 25 | $386.4M | $246.3M | ||
| Q2 25 | $327.3M | $445.9M | ||
| Q1 25 | $343.9M | $493.6M | ||
| Q4 24 | $316.1M | $484.6M | ||
| Q3 24 | $319.3M | $453.8M | ||
| Q2 24 | $273.9M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $25.7M | $372.2M | ||
| Q3 25 | $24.9M | $376.7M | ||
| Q2 25 | $26.4M | $580.5M | ||
| Q1 25 | $20.5M | $583.4M | ||
| Q4 24 | $20.7M | $585.3M | ||
| Q3 24 | $22.2M | — | ||
| Q2 24 | $20.3M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $1.9B | $693.1M | ||
| Q3 25 | $1.9B | $727.2M | ||
| Q2 25 | $1.9B | $757.8M | ||
| Q1 25 | $1.8B | $798.5M | ||
| Q4 24 | $1.8B | $778.3M | ||
| Q3 24 | $1.8B | $749.6M | ||
| Q2 24 | $1.8B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $2.4B | $1.3B | ||
| Q3 25 | $2.5B | $1.3B | ||
| Q2 25 | $2.5B | $1.5B | ||
| Q1 25 | $2.4B | $1.6B | ||
| Q4 24 | $2.4B | $1.6B | ||
| Q3 24 | $2.4B | $1.5B | ||
| Q2 24 | $2.4B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.01× | 0.54× | ||
| Q3 25 | 0.01× | 0.52× | ||
| Q2 25 | 0.01× | 0.77× | ||
| Q1 25 | 0.01× | 0.73× | ||
| Q4 24 | 0.01× | 0.75× | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $38.1M | — |
| Free Cash FlowOCF − Capex | $12.4M | — |
| FCF MarginFCF / Revenue | 3.2% | — |
| Capex IntensityCapex / Revenue | 6.6% | — |
| Cash ConversionOCF / Net Profit | 3.74× | — |
| TTM Free Cash FlowTrailing 4 quarters | $137.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $38.1M | $43.7M | ||
| Q3 25 | $79.1M | $60.8M | ||
| Q2 25 | $41.5M | $12.0M | ||
| Q1 25 | $56.7M | $35.5M | ||
| Q4 24 | $81.8M | $33.1M | ||
| Q3 24 | $54.4M | $53.9M | ||
| Q2 24 | $14.4M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $12.4M | $43.5M | ||
| Q3 25 | $62.8M | $57.0M | ||
| Q2 25 | $21.1M | $9.3M | ||
| Q1 25 | $40.8M | $26.9M | ||
| Q4 24 | $62.1M | $31.0M | ||
| Q3 24 | $39.4M | $49.8M | ||
| Q2 24 | $-3.5M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 3.2% | 22.1% | ||
| Q3 25 | 16.0% | 31.7% | ||
| Q2 25 | 5.8% | 5.1% | ||
| Q1 25 | 12.3% | 15.9% | ||
| Q4 24 | 18.3% | 16.6% | ||
| Q3 24 | 11.2% | 29.6% | ||
| Q2 24 | -1.1% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 0.1% | ||
| Q3 25 | 4.2% | 2.2% | ||
| Q2 25 | 5.6% | 1.5% | ||
| Q1 25 | 4.8% | 5.1% | ||
| Q4 24 | 5.8% | 1.1% | ||
| Q3 24 | 4.3% | 2.4% | ||
| Q2 24 | 5.6% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.74× | — | ||
| Q3 25 | 5.54× | 11.20× | ||
| Q2 25 | 0.90× | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | 9.93× | — | ||
| Q3 24 | 3.95× | — | ||
| Q2 24 | 1.80× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DIOD
| Distributor | $253.1M | 65% |
| Direct Sales | $138.5M | 35% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
